Four States End Medicaid Coverage for Weight-Loss Drugs, Leading to Dramatic Prescription Decline
Four U.S. states—California, New Hampshire, Pennsylvania, and South Carolina—ceased Medicaid coverage for GLP-1 medications approved for weight loss on January 1, 2026. This decision was driven by concerns over the high cost of these drugs. A study published in JAMA revealed that following this policy change, prescriptions for weight-loss GLP-1s in these four states plummeted by 84% relative to states that maintained coverage. Specifically, quarterly prescriptions per 100,000 Medicaid beneficiaries in the affected states dropped from 2,914 to 421 between the final quarter of 2025 and the first quarter of 2026. Lead author Bryant Shuey, an assistant professor of medicine at the University of Pittsburgh, noted that this change could mean between 175,500 and 526,600 fewer beneficiaries filling these prescriptions across the four states.